

EDITORIAL COMMENT

From Description to Action

Atherosclerotic Cardiovascular Disease in Adults With Congenital Heart Disease*



Beatriz Fernandez-Campos, MD,^a Katia Bravo-Jaimes, MD^b

Congenital heart disease (CHD) represents the most common birth defect worldwide, and despite the variable access to care that exists across the globe, congenital heart surgery has allowed a substantial number of children with CHD to survive to adulthood in low- and middle-income countries. In fact, the number of adults with CHD in Latin America is estimated to continue growing by 5 to 6% each year.¹ Despite improved surgical results across recent eras, adults with CHD have a reduced life expectancy and unique cardiovascular risk profile when compared to age-matched controls without CHD.^{2,3} In this context, quantifying traditional atherosclerotic cardiovascular disease (ASCVD) risk factors is of extreme importance as they are modifiable and associated with coronary artery disease,⁴ atrial fibrillation,⁵ heart failure hospitalization,⁶ and all-cause mortality^{3,6} in the adult congenital heart disease (ACHD) population.

In this issue of *JACC: Advances*, Garcia-Cruz et al⁷ describe traditional ASCVD risk factors among 1,171 adults with CHD seen at a tertiary-level center in Mexico City. The cohort was young (mean age 31 years) with predominantly (83%) simple and moderate complexity CHD, where the most frequent ASCVD risk factors were low high-density

lipoprotein cholesterol levels, insulin resistance, and prediabetes affecting up to 50% of the study population. Systemic arterial hypertension and obesity affected a third of their cohort, while type 2 diabetes mellitus affected 20% of them. Despite no control group being included in the study, these findings were similar to those seen in the general Mexican population.^{8,9} Of note, almost 15% of their cohort was diagnosed with type 2 diabetes mellitus at the time of the study, revealing barriers to ASCVD risk surveillance in the primary and secondary care levels.


The authors also showed significant differences in the prevalence of ASCVD risk factors according to CHD complexity with complex CHD being associated with lower odds of metabolic syndrome and systemic arterial hypertension but higher odds of type 2 diabetes mellitus and hyperuricemia. The latter as a result of secondary erythrocytosis induced by chronic cyanosis and abnormal uric acid excretion¹⁰ or medication side effects (ie, diuretics), which was not reported. The small sample size and younger age of adults with complex CHD in this cohort may explain the inverse association with hypertension and metabolic syndrome, which is not consistent with other studies.¹¹ Furthermore, patients with cyanotic CHD seem to have similar subclinical carotid and coronary atherosclerosis compared to controls,¹² and therefore risk factor optimization needs to be addressed during lifelong CHD care.

An important and positive finding to highlight is that <5% of this cohort reported active smoking, which is significantly lower than the smoking prevalence seen in the Mexican adult population, estimated at around 19.5%.¹³ Mexico has achieved a 45% decline in smoking rates from 2000 to 2020,¹⁴ though higher frequency is still seen in urban areas and

*Editorials published in *JACC: Advances* reflect the views of the authors and do not necessarily represent the views of *JACC: Advances* or the American College of Cardiology.

From the ^aDivision of Cardiology, University Health Network and Mount Sinai Health System, University of Toronto, Toronto, Ontario, Canada; and the ^bDepartment of Cardiovascular Medicine, Mayo Clinic Florida, Jacksonville, Florida, USA.

The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors' institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the [Author Center](#).



significant variation across regions and educational status exists.¹³ Although socioeconomic status and regional variation were not described in this cohort and underreporting among nondaily smokers cannot be completely ruled out, other studies in the United States¹⁵ and Europe¹⁶ consistently report similar findings, probably representing a global phenomenon: ACHD are aware of smoking consequences and are less likely to smoke. This is the result of all stakeholders consistently sharing the same message and coordinating advocacy, education, and empowerment efforts that can modify harmful behaviors in the ACHD population.

We congratulate Garcia-Cruz et al⁷ for their efforts in improving our understanding of the current status of ASCVD risk factors in the Mexican ACHD population. We encourage other ACHD centers in

Latin America to report their data including sex-specific risk factors and how social determinants of health influence them. More importantly, we make a call to action towards optimizing ASCVD risk factors in the ACHD population at a global level (Figure 1). Children with CHD are at risk of acquiring unhealthy lifestyles and dietary habits early in their lives, affecting their future potential, life expectancy, and long-term outcomes. A mantra coined by Dr Michael Gatzoullis will likely remain relevant in the next few decades: to encourage children and adults with CHD to be “slim and athletic,” highlighting the need to promote cardiovascular prevention and cardiorespiratory fitness in our ACHD clinics and favoring health literacy. This, however, is an arduous task that cannot be accomplished without a multidisciplinary congenital heart team

approach, education, patient empowerment, advocacy, and lifelong CHD care.

FUNDING SUPPORT AND AUTHOR DISCLOSURES

The authors have reported that they have no relationships relevant to the contents of this paper to disclose.

ADDRESS FOR CORRESPONDENCE: Dr Katia Bravo-Jaimes, Department of Cardiovascular Medicine, Mayo Clinic Florida, 4500 San Pablo Road S, Jacksonville, Florida 32224, USA. E-mail: Bravo.katia@mayo.edu.

REFERENCES

1. Araujo JJ, Rodríguez-Monserrate CP, Elizari A, et al. Position statement for the development of adult congenital heart disease units in Latin America and the Caribbean: recommendations by the Adult Congenital Heart Disease Chapter and Pediatric Cardiology Council of the Interamerican Society of Cardiology. *Int J Cardiol Congenit Heart Dis.* 2023;13:100461. <https://doi.org/10.1016/j.ijchd.2023.100461>
2. Afilalo J, Therrien J, Pilote L, Ionescu-Iltu R, Martucci G, Marelli AJ. Geriatric congenital heart disease: burden of disease and predictors of mortality. *J Am Coll Cardiol.* 2011;58(14):1509–1515. <https://doi.org/10.1016/j.jacc.2011.06.041>
3. Tutarel O, Kempny A, Alonso-Gonzalez R, et al. Congenital heart disease beyond the age of 60: emergence of a new population with high resource utilization, high morbidity, and high mortality. *Eur Heart J.* 2013;35(11):725–732. <https://doi.org/10.1093/eurheartj/ehd257>
4. Giannakoulas G, Dimopoulos K, Engel R, et al. Burden of coronary artery disease in adults with congenital heart disease and its relation to congenital and traditional heart risk factors. *Am J Cardiol.* 2009;103(10):1445–1450. <https://doi.org/10.1016/j.amjcard.2009.01.353>
5. Labombarda F, Hamilton R, Shohoudi A, et al. Increasing prevalence of atrial fibrillation and permanent atrial arrhythmias in congenital heart disease. *J Am Coll Cardiol.* 2017;70(7):857–865. <https://doi.org/10.1016/j.jacc.2017.06.034>
6. Egbe AC, Miranda WR, Jain CC, et al. Temporal changes in clinical characteristics and outcomes of adults with congenital heart disease. *Am Heart J.* 2023;264:1–9. <https://doi.org/10.1016/j.ahj.2023.05.025>
7. García-Cruz E, Manzur-Sandoval D, Gopar-Nieto R, et al. Cardiometabolic risk factors in Mexican adults with congenital heart disease. *JACC: Adv.* 2023;2:100596.
8. Campos-Nonato I, Galván-Valencia Ó, Hernández-Barrera L, Oviedo-Solís C, Barquera S. Prevalencia de obesidad y factores de riesgo asociados en adultos mexicanos: resultados de la Ensanut 2022. *Salud Publica Mex.* 2023;65:s238–s247. <https://doi.org/10.21149/14809>
9. Basto-Abreu A, López-Olmedo N, Rojas-Martínez R, et al. Prevalencia de prediabetes y diabetes en México: Ensanut 2022. *Salud Publica Mex.* 2023;65:s163–s168. <https://doi.org/10.21149/14832>
10. Rodríguez-Hernández JL, Rodríguez-González F, Riaño-Ruiz M, Martínez-Quintana E. Risk factors for hyperuricemia in congenital heart disease patients and its relation to cardiovascular death. *Congenit Heart Dis.* 2018;13(5):655–662. <https://doi.org/10.1111/chd.12620>
11. Umaphathi KK, Thavamani A, Bosco G, Dhanpalreddy H, Nguyen HH. Prevalence of metabolic syndrome in young adults with congenital heart disease. *Am J Cardiol.* 2022;179:90–95. <https://doi.org/10.1016/j.amjcard.2022.05.031>
12. Tarp JB, Radu MD, De Backer O, et al. Intra-vascular assessment of coronary arteries in patients with cyanotic congenital heart disease. *EuroIntervention.* 2019;14(17):1744–1750. <https://doi.org/10.4244/eij-d-18-00882>
13. Ritchie H, Roser M. What can we do to reduce smoking? Accessed July 27, 2023. <https://ourworldindata.org/smoking#pricing-and-taxes>
14. Barrera-Núñez DA, López-Olmedo N, Zavala-Arciniega L, Barrientos-Gutiérrez I, Reynales-Shigematsu LM. Consumo de tabaco y uso de cigarro electrónico en adolescentes y adultos mexicanos. Ensanut Continua 2022. *Salud Publica Mex.* 2023;65:s65–s74. <https://doi.org/10.21149/14830>
15. Lui GK, Rogers IS, Ding VY, et al. Risk estimates for atherosclerotic cardiovascular disease in adults with congenital heart disease. *Am J Cardiol.* 2017;119(1):112–118. <https://doi.org/10.1016/j.amjcard.2016.09.023>
16. Engelfriet PM, Drenthen W, Pieper PG, et al. Smoking and its effects on mortality in adults with congenital heart disease. *Int J Cardiol.* 2008;127(1):93–97. <https://doi.org/10.1016/j.ijcard.2007.05.008>

KEY WORDS adult congenital heart disease, atherosclerosis, cardiovascular, risk factors, global health, Latin America